# Parkinson Disease

Parkinson disease is a clinical diagnosis requiring bradykinesia plus rest tremor or rigidity. Confirm the parkinsonian syndrome, identify exclusion criteria and atypical red flags, use dopaminergic response as longitudinal diagnostic evidence, and individualize symptomatic therapy while actively screening motor and nonmotor disability.

**Clinical question:** How should clinicians diagnose Parkinson disease, distinguish mimics, and manage evolving motor and nonmotor symptoms?

Updated: 2026-08-21T02:02:28.331856+00:00

## What matters in practice
- Diagnose parkinsonism only when bradykinesia is accompanied by rigidity or limb rest tremor; Parkinson disease remains a clinical diagnosis based on history and neurologic examination. [2][19][21]
- Apply Movement Disorder Society criteria after establishing parkinsonism: clinically established PD requires no absolute exclusion criteria, at least two supportive criteria, and no red flags. [19][21]
- Early severe autonomic failure, recurrent early falls, rapid gait decline, bulbar or inspiratory respiratory dysfunction, cerebellar signs, supranuclear gaze palsy, cortical deficits, or poor high-dose levodopa response should redirect evaluation toward secondary or atypical parkinsonism. [21][22]
- A clear dopaminergic response and levodopa-induced dyskinesia support idiopathic PD; absence of response to high-dose levodopa despite at least moderate severity is an exclusion criterion. [19][21]
- Treat symptomatic disability rather than a diagnostic label alone; oral levodopa remains the most effective and widely used motor therapy, while therapy selection should be individualized for motor and nonmotor burden. [2][11]
- At every longitudinal review, assess motor fluctuations, dyskinesia, sleep, mood, cognition, autonomic symptoms, and impulse-control behaviors because nonmotor burden substantially affects quality of life and health care use. [3][7]

## Confirm parkinsonism before labeling Parkinson disease

Use the examination to establish the motor syndrome, then classify diagnostic certainty.

Parkinson disease is diagnosed clinically. Establish parkinsonism by documenting bradykinesia with either rigidity or rest tremor; the Movement Disorder Society definition does not require postural instability. During repetitive movements, distinguish true bradykinesia by progressive decrement in amplitude or speed rather than generalized slowness alone. [2][18][19][21]

After confirming parkinsonism, obtain a medication history that specifically identifies dopamine receptor blockers and dopamine-depleting agents. Parkinsonism temporally compatible with these exposures is an MDS absolute exclusion criterion for PD and should prompt a drug-induced parkinsonism pathway rather than empiric diagnostic labeling. [21]

Record laterality, limb rest tremor, progression, and nonmotor symptoms at baseline. Persistent asymmetry, rest tremor, a progressive course, and a good levodopa response support idiopathic PD, but no early biomarker definitively establishes PD or reliably separates it from all neurodegenerative mimics. [19][24]
- Supportive MDS features: clear beneficial dopaminergic response, levodopa-induced dyskinesia, limb rest tremor, and either olfactory loss or cardiac sympathetic denervation on MIBG scintigraphy. [19][21]
- Clinically established PD: parkinsonism, no absolute exclusion criteria, at least two supportive criteria, and no red flags. [19][21]
- Clinically probable PD: parkinsonism, no absolute exclusion criteria, and red flags counterbalanced by supportive criteria; more than two red flags are not allowed. [19][21]

*Movement Disorder Society diagnostic framework for clinical Parkinson disease. [19][21]*

| Decision step | Finding | Interpretation and next action |
| --- | --- | --- |
| Establish motor syndrome | Bradykinesia plus rigidity or rest tremor | Parkinsonism is present; proceed to exclusion criteria, supportive features, and red flags. [19][21] |
| Identify absolute exclusion | Cerebellar abnormalities, supranuclear gaze palsy, cortical sensory loss, ideomotor apraxia, progressive aphasia, dopamine-blocker/depleter exposure compatible with drug-induced parkinsonism, or normal presynaptic dopaminergic imaging | Do not diagnose PD on MDS criteria; pursue the alternative syndrome or cause. [21] |
| Assess supportive evidence | Clear dopaminergic benefit, levodopa-induced dyskinesia, limb rest tremor, olfactory loss, or cardiac sympathetic denervation on MIBG scintigraphy | Supports PD and can counterbalance limited red flags for clinically probable PD. [19][21] |
| Assign established PD | At least two supportive criteria and no red flags | Classify as clinically established PD after exclusion criteria are absent. [19][21] |
| Assign probable PD | One red flag with one supportive criterion, or two red flags with at least two supportive criteria | Classify as clinically probable PD only when exclusion criteria are absent; reassess diagnosis longitudinally. [19][21] |

## Use red flags to redirect evaluation toward secondary and atypical parkinsonism

Atypical features change the diagnostic target and should not be explained away as uncomplicated PD.

Actively query the tempo of gait failure, falls, autonomic dysfunction, dysphagia, dysarthria, stridor, cognitive-language syndrome, and ocular motor symptoms. Rapid gait progression to wheelchair dependence within 5 years, recurrent balance-related falls within 3 years, severe autonomic failure within 5 years, early bulbar dysfunction, inspiratory respiratory dysfunction, and disproportionate anterocollis or contractures are MDS red flags. [21]

Examine for cerebellar signs, vertical supranuclear gaze palsy, cortical sensory loss, ideomotor apraxia, and progressive aphasia. These findings are exclusion criteria because they favor alternative neurodegenerative diagnoses such as multiple system atrophy, progressive supranuclear palsy, or corticobasal syndrome rather than idiopathic PD. [21][22]

Use longitudinal levodopa responsiveness diagnostically. A gratifying response to an adequate dopaminergic trial supports PD; no response to high-dose levodopa in at least moderate disease is an exclusion criterion. Conversely, some patients with vascular parkinsonism obtain levodopa benefit, so a levodopa trial remains appropriate when vascular parkinsonism is suspected. [21][23][24]
- Drug-induced parkinsonism: correlate symptom onset with dopamine receptor blockade or dopamine-depleting therapy; this exposure pattern is an MDS exclusion criterion for PD. [21]
- Vascular parkinsonism: brain vascular disease supports but does not prove causality; DaTSCAN is usually normal, although a focal basal-ganglia infarct can produce an abnormal scan. Manage vascular risk factors and rehabilitation, and offer a levodopa trial. [23]
- Dementia with Lewy bodies: parkinsonism may be axial and less asymmetric, with less dramatic levodopa response; one of bradykinesia, rest tremor, or rigidity is sufficient for the motor feature in probable DLB criteria. [5]
- Progressive supranuclear palsy or corticobasal syndrome: supranuclear gaze palsy, cortical sensory loss, apraxia, or progressive aphasia should supersede a PD diagnosis. [21]

*High-yield findings that should shift the differential beyond idiopathic Parkinson disease. [5][21][23]*

| Pattern | Discriminator | Clinical next step |
| --- | --- | --- |
| Drug-induced parkinsonism | Dopamine receptor blocker or dopamine-depleting agent exposure consistent with symptom onset | Treat as secondary parkinsonism and reassess the need for the implicated drug; do not classify as PD by MDS criteria. [21] |
| Vascular parkinsonism | Cerebrovascular disease on imaging; DaTSCAN usually normal, but infarction involving basal ganglia may make it abnormal | Optimize vascular risk control and rehabilitation; conduct a levodopa trial because partial response can occur. [23] |
| Multiple system atrophy pattern | Severe autonomic failure early in disease, inspiratory respiratory dysfunction, rapid progression, abnormal posture, or early instability | Refer for movement-disorders assessment and evaluate the autonomic and respiratory phenotype. [18][21] |
| Progressive supranuclear palsy pattern | Supranuclear gaze palsy or early recurrent balance-related falls | Do not apply an uncomplicated PD label; evaluate for PSP-spectrum disease. [21] |
| Corticobasal syndrome pattern | Cortical sensory loss, clear limb ideomotor apraxia, or progressive aphasia | Pursue corticobasal syndrome or another cortical neurodegenerative diagnosis. [21] |
| Dementia with Lewy bodies pattern | Less asymmetric, more axial extrapyramidal signs and less dramatic levodopa response | Assess cognition, visuospatial-executive function, and associated Lewy body features. [5] |

## Match dopaminergic therapy to disabling motor symptoms and evolving complications

Symptomatic treatment should be individualized to functional impairment, adverse effects, and patient priorities.

Oral levodopa remains the most effective and widely used treatment for PD motor symptoms. Select therapy according to functional disability, motor phenotype, adverse-effect vulnerability, current medications, and nonmotor burden rather than treating imaging or diagnostic certainty alone. [2][11]

A meaningful dopaminergic response is both therapeutic and diagnostically supportive. Document the target symptom, functional change, timing of benefit, adverse effects, and whether dyskinesia emerges; levodopa-induced dyskinesia is a supportive feature for PD in MDS criteria. [19][21][24]

For wearing-off or dyskinesia, identify the relationship of symptoms to individual levodopa doses before adding therapy. Reviews of motor-complication management address catechol-O-methyltransferase inhibitors, selective MAO-B inhibitors, istradefylline, amantadine formulations, clozapine, and device-assisted medication therapies; choice requires phenotype-specific assessment rather than a uniform escalation sequence. [8][15]
- Avoid abrupt discontinuation or rapid dose reduction of carbidopa/levodopa extended-release capsules. [1]
- Nonselective MAO inhibitors are contraindicated with carbidopa/levodopa extended-release capsules; discontinue a nonselective MAO inhibitor at least 2 weeks before starting the capsule formulation. [1]
- When selective MAO-B inhibitors such as rasagiline or selegiline are used with carbidopa/levodopa extended-release capsules, monitor for orthostatic hypotension. [1]
- Ask specifically about unintentional sleep episodes during activities of daily living when prescribing carbidopa/levodopa extended-release capsules. [1]

### When to consider procedural therapy

For medication-refractory motor complications, deep brain stimulation and ablative or lesioning procedures are therapeutic options. Refer patients with troublesome fluctuations, dyskinesia, or tremor despite optimized medical management to a multidisciplinary movement-disorders and functional-neurosurgery program for selection assessment. [14]
- Deep brain stimulation is an invasive neuromodulation therapy; focused ultrasound is a noninvasive therapeutic approach under evolving neuromodulation paradigms. [13][16]
- Procedure selection should account for the motor target, medication response, comorbidities, cognition and neuropsychiatric profile, and the patient’s ability to participate in longitudinal programming and follow-up. [2][14]

*Motor-treatment decisions supported by the clinical phenotype and medication safety constraints. [1][2][8][11][14][15]*

| Clinical decision | Action | Key monitoring or constraint |
| --- | --- | --- |
| Disabling early motor symptoms | Use individualized symptomatic dopaminergic treatment; oral levodopa is the most effective and widely used motor therapy. [2][11] | Document objective and functional response, adverse effects, and emergence of dyskinesia. [19][21] |
| Uncertain diagnosis | Use response to an adequate dopaminergic trial as longitudinal evidence while continuing to evaluate red flags. [21][24] | Absent high-dose levodopa response in at least moderate disease is an MDS exclusion criterion. [21] |
| Wearing-off or dyskinesia | Characterize dose timing, then consider therapies reviewed for motor complications, including COMT inhibitors, MAO-B inhibitors, istradefylline, amantadine formulations, and device-assisted therapies. [8][15] | Choose according to the complication phenotype and adverse-effect profile. [8][15] |
| Carbidopa/levodopa extended-release capsule with MAO therapy | Do not combine with nonselective MAO inhibitors; allow a 2-week washout before initiation. [1] | With rasagiline or selegiline, monitor for orthostatic hypotension. [1] |
| Medication-refractory motor complications | Refer for DBS or lesioning-procedure evaluation. [14] | Use multidisciplinary selection because procedural therapy is not a substitute for correcting an atypical diagnosis. [14][21] |

## Screen nonmotor disability systematically and incorporate caregiver-relevant risks

Nonmotor symptoms often drive quality of life, hospitalization, and treatment tolerability.

Do not restrict follow-up to tremor, rigidity, gait, or medication timing. Nonmotor symptoms are integral to PD, can be prominent during the premotor phase, and substantially influence quality of life, hospital use, and care costs. Use structured questioning for sleep, mood, cognition, autonomic symptoms, fatigue, pain, psychosis, and impulse-control behaviors at routine reviews. [3][7]

When cognitive decline is suspected, bedside assessment should include visuospatial and executive tasks. A clock-drawing exercise can reveal visuospatial-executive impairment but does not replace formal neuropsychological testing. Relatively preserved episodic memory with improved recall after prompting supports executive retrieval failure described in DLB, whereas impaired recall and recognition suggest medial temporal dysfunction. [5]

Assess orthostatic symptoms and medication-associated hypotension whenever levodopa formulations are combined with selective MAO-B inhibitors. Clarify daytime sleepiness and sudden sleep episodes before driving or safety-sensitive activity, particularly with carbidopa/levodopa extended-release capsules. [1]
- Ask the patient and care partner separately about hallucinations, sleep behaviors, mood symptoms, cognitive change, and compulsive behaviors because these may not be volunteered. Nonmotor burden is a major determinant of patient and caregiver quality of life. [3][7]
- If cognitive impairment precedes or closely accompanies parkinsonism, reconsider DLB and document visuospatial-executive performance rather than relying on memory screening alone. [5]
- If recurrent falls, dysphagia, stridor, severe early autonomic dysfunction, or rapid gait decline develops, reopen the diagnosis and evaluate for atypical parkinsonism. [21]

*Follow-up domains that change Parkinson disease treatment safety or diagnostic confidence. [1][3][5][7][21]*

| Domain | Focused assessment | Decision consequence |
| --- | --- | --- |
| Motor response | Relation of benefit, wearing-off, dyskinesia, and gait impairment to each dopaminergic dose | Distinguish medication-responsive disability from motor complications or an atypical progression pattern. [15][21] |
| Autonomic symptoms | Orthostatic symptoms and severity/timing of autonomic failure | Monitor hypotension with selective MAO-B inhibitor plus carbidopa/levodopa extended-release therapy; severe autonomic failure within 5 years is a PD red flag. [1][21] |
| Falls and gait | Timing of balance-related falls and rate of gait progression | Recurrent falls within 3 years or wheelchair dependence within 5 years should prompt atypical-parkinsonism reassessment. [21] |
| Sleep and alertness | Daytime sleepiness and sudden sleep episodes during daily activities | Address safety-sensitive activities and review carbidopa/levodopa extended-release exposure. [1] |
| Cognition | Clock drawing, attention, visuospatial-executive function, recall with prompting, and need for formal neuropsychological testing | Pattern may strengthen suspicion for DLB or another dementia syndrome. [5] |

## Reassess the diagnosis when disease evolution conflicts with idiopathic PD

Clinical evolution and treatment response are diagnostic data, not merely treatment outcomes.

Revisit diagnostic certainty when red flags accumulate, levodopa response is absent or unexpectedly weak, or the syndrome becomes rapidly symmetric, axial, autonomic, bulbar, ocular motor, cerebellar, cortical, or cognitive-language predominant. MDS probable PD permits only up to two red flags, each counterbalanced by supportive criteria; clinically established PD permits none. [19][21]

An abnormal presynaptic dopaminergic study is not synonymous with idiopathic PD, and normal presynaptic dopaminergic imaging is an MDS exclusion criterion. In suspected vascular parkinsonism, DaTSCAN is usually normal but can be abnormal after focal basal-ganglia infarction; interpret imaging within the clinical and structural-imaging context. [21][23]

Refer early to a movement-disorders specialist when the phenotype is atypical, the diagnosis remains uncertain, motor complications become difficult to control, or functional-neurosurgical therapy is contemplated. Multidisciplinary care is central to personalized PD management because motor and nonmotor disability require coordinated treatment planning. [2][14]
- Do not treat a single red flag as pathognomonic for a specific alternative disorder; red flags are relative arguments against PD and should accelerate focused diagnostic reassessment. [17][24]
- Do not use vascular changes on brain imaging alone to diagnose vascular parkinsonism, because cerebrovascular disease frequently coexists with PD in older adults. [23]
- Continue to document dopaminergic benefit, dyskinesia, falls, autonomic severity, bulbar function, eye movements, and cortical signs at serial visits because these observations determine whether MDS criteria remain coherent. [19][21]

*Triggers for diagnostic escalation during follow-up. [19][21][23]*

| Trigger | Why it matters | Next action |
| --- | --- | --- |
| No meaningful response to high-dose levodopa despite at least moderate severity | This is an MDS absolute exclusion criterion for PD. [21] | Reassess adherence, dose exposure, phenotype, and alternative parkinsonian syndromes. [21] |
| More than two MDS red flags | MDS probable PD cannot be assigned when more than two red flags are present. [19][21] | Reclassify diagnostic confidence and pursue atypical or secondary causes. [19][21] |
| Normal presynaptic dopaminergic imaging | This is an MDS absolute exclusion criterion for PD. [21] | Redirect evaluation to nondegenerative, drug-induced, vascular, or other alternative causes as clinically appropriate. [21][23] |
| Focal basal-ganglia infarct with abnormal DaTSCAN | An abnormal scan may reflect infarction rather than idiopathic PD. [23] | Integrate structural imaging, vascular phenotype, and levodopa trial response. [23] |

## References
1. These highlights do not include all the information needed to use CARBIDOPA AND LEVODOPA EXTENDED-RELEASE CAPSULES safely and effectively. See full prescribing information for CARBIDOPA AND LEVODOPA EXTENDED-RELEASE CAPSULES.
  
CARBIDOPA and LEVODOPA extended-release capsules, for oral use
  
Initial U.S. Approval: 1975 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=beedd327-bbc5-4f17-838a-4e72bf0867f0&type=display
2. Parkinson disease - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/147
3. Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected | Practical Neurology — pn.bmj.com — https://pn.bmj.com/content/14/5/310
4. Parkinson’s Disease — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMra2401857
5. Dementia with Lewy bodies: a practical guide to clinical diagnosis and management | Practical Neurology — pn.bmj.com — https://pn.bmj.com/content/26/1/4
6. Compliance with National and International Guidelines in ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1155/2023/6667339
7. Update on treatments for nonmotor symptoms of Parkinson's ... — movementdisorders.onlinelibrary.wiley.com — https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.27602
8. International Parkinson and movement disorder society ... — movementdisorders.onlinelibrary.wiley.com — https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.27372
9. Reported Symptoms in Prodromal and Early Motor ... — movementdisorders.onlinelibrary.wiley.com — https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mdc3.70007
10. Longitudinal Study of Treatment Variability for Parkinson's ... — movementdisorders.onlinelibrary.wiley.com — https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mdc3.70232
11. Update on the Management of Parkinson's Disease for ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1155/2020/9131474
12. A Systematic Review on Disease‐Modifying Therapies in ... — ascpt.onlinelibrary.wiley.com — https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.70315?af=R
13. Translational prospectives for deep brain stimulation and low-intensity focused ultrasound neuromodulation: IFCN Handbook chapter — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2467981X26000260
14. Surgical Treatment of Parkinson's Disease: Devices and ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1878747923012576
15. Medical Management and Prevention of Motor Complications in Parkinson's Disease — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S187874792301245X
16. Neurosurgical treatments for Parkinson's disease — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2214751926000988
17. Revisiting the 2015 MDS diagnostic criteria for Parkinson disease: insights from autopsy-confirmed cases — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12748991
18. Clinical Aspects of the Differential Diagnosis of Parkinson’s Disease and Parkinsonism — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9163948
19. Defining Parkinson’s Disease: Past and Future — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11492139
20. Recognizing Atypical Parkinsonisms: “Red Flags” and ... - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5961706
21. Table 1, The clinical diagnostic criteria for Parkinson’s disease, based on the Movement Disorder Society guidelines - Parkinson’s Disease - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK536715/table/Ch6-t0001
22. Diagnosis and Differential Diagnosis of Parkinson Disease — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/31733693
23. The Differential Diagnosis of Parkinson's Disease - NCBI — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK536715
24. 1.2 Clinical presentation and diagnosis of Parkinson's disease - Where are We? Continuous Dopaminergic Stimulation for Parkinson's Disease - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK604706

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.